Non-peptide Linkers for Antibody-Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face limitations in delivering drugs effectively to cancer cells due to the limited chemical space of natural peptides used as linkers, which restricts the diversity of non-peptide linkers that can be cleaved by lysosomal enzymes, affecting both efficacy and safety.
Innovation Solution
Development of non-peptide linkers that can be effectively cleaved by lysosomal enzymes, specifically designed for use in antibody-drug conjugates to enhance drug delivery to tumor cells, including antibodies targeting Ly6E, STEAP1, CD79b, MUC16, and HER2 for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide linkers are used to connect the drug with the antibody, then the ADC shows relative stability in vivo and efficient drug release in tumor, but the chemical space is limited and diversity of linkers is restricted
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the linker from natural peptides to non-peptide structures. The non-peptide linkers maintain the cleavable functionality while expanding the chemical space through diverse structural parameters including different backbone compositions, side chain configurations, and functional group arrangements, thereby achieving both stability and diversity.
Solution Approach 2:
The patent employs composite materials by creating hybrid linker structures that combine elements of peptide and non-peptide chemistry. These composite linkers incorporate stable non-peptide backbones with functional groups that mimic peptide behavior, allowing them to be cleaved by lysosomal enzymes while providing greater chemical diversity and structural versatility.
2Ease of operation
If natural peptide linkers are used, then the linker can be effectively cleaved by lysosomal enzymes, but the variety and novelty of linker properties are limited
Solution Approach 1:
The patent applies mechanics substitution by replacing the natural peptide-based chemical recognition system with a non-peptide chemical system. The non-peptide linkers are designed with specific functional groups and structural motifs that are recognized and cleaved by lysosomal enzymes, substituting the traditional peptide recognition mechanism while enabling access to novel chemical properties and structures.
3Adaptability or versatility
If diverse non-peptide linkers are developed, then novel beneficial properties can be achieved, but the design and optimization complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the non-peptide linker design into modular components including a stable backbone, functional groups for enzyme recognition, and drug attachment sites. This segmented approach allows systematic optimization of each component independently while maintaining overall functionality, thereby managing design complexity through modular architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new non-peptide linkers improve the stability and targeted release of drugs within cancer cells, potentially increasing the therapeutic index and efficacy of ADCs while expanding the chemical space for novel properties not afforded by peptide linkers.
Implementation Method 1
non-peptide linkers which act like peptides and can be effectively cleaved by lysosomal proteases
Data Source
AI summary
The invention provides immunoconjugates and methods of using the same.